CDX2 and adenocarcinoma: In our study, an immunohistochemistry panel with specific markers was performed in all MiNEN cases, evidencing the presence of both neuroendocrine components (chromogranin A, synaptophysin, CD56, CK35BH11) and adenocarcinoma cells (AE1/AE2, CDX2, CK7, CK20).